Quantum BioPharma News - September 2026
Quantum BioPharma Jumps 11% on a New CEO Hire — But Can a Licensing Bet Deliver Real Revenue for a $30 Million Company?
Shares of Quantum BioPharma (NASDAQ: QNTM) surged +10.8% to $4.30 on September 24, defying a weak biotech tape, after its licensee Unbuzzd Wellness named...
🟢 Quantum BioPharma is trading 10.8% up today after licensee Unbuzzd Wellness appointed Michael Zapolin CEO
Quantum BioPharma is trading at $4.30, up 10.82%, with Unbuzzd Wellness’s CEO appointment appearing to be the clearest company-specific catalyst. - The...
🟢 Quantum BioPharma is trading 13.5% up today — catalyst unconfirmed
Quantum BioPharma is trading 13.5% higher at $4.20, with no specific catalyst confirmed. - No new company-specific announcement was identified on September...
🟢 Quantum BioPharma is trading 10.62% up today after renewed attention to FDA clearance for its Phase 2 Lucid-MS trial
Quantum BioPharma is trading 10.62% up at $3.54 after renewed attention to FDA clearance for its Phase 2 Lucid-MS trial in multiple sclerosis. - A September...
🔴 Quantum BioPharma is trading 10.34% down today as broader risk-off sentiment weighs on equities
Quantum BioPharma is trading 10.34% down now at $3.21 as broader risk-off sentiment weighs on equities. - The S&P 500, Nasdaq Composite, and Dow Jones are...
Quantum BioPharma's FDA Green Light for Its MS Drug Sparks a Rally — But Can a $22 Million Company Really Crack a $38 Billion Market?
Shares of Quantum BioPharma (NASDAQ: QNTM) surged as much as 10.6% to $3.64 on September 9 — bucking a down market — after fresh coverage highlighted the FDA's...
🟢 Quantum BioPharma is trading 10.64% up today after FDA clearance for Lucid-MS Phase 2 testing
Quantum BioPharma is trading 10.64% up now at $3.64 after September 9, 2026 coverage spotlighted FDA clearance for Lucid-MS to enter Phase 2 testing in...
🟢 Quantum BioPharma is trading 5.78% up today after FDA-clearance coverage of Lucid-MS Phase 2 trials
Quantum BioPharma is trading 5.78% up now at $3.48 after September 9, 2026 coverage highlighted FDA clearance to begin Phase 2 trials of Lucid-MS, its...